Follow us on Twitter
This page is updated frequently with new Neoplasm-related patent applications. Subscribe to the Neoplasm RSS feed to automatically get the update: related Neoplasm RSS feeds. RSS updates for this page: Neoplasm RSS
|| List of recent Neoplasm-related patents
| Diagnostic gene marker panel for colorectal cancer|
The present invention relates generally to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention relates to a method of screening for the onset, predisposition to the onset and/or progression of a neoplasm by screening for changes to the methylation levels of a panel of gene markers including bcat1, ikzf1, irf4, grasp and/or cahm.
Commonwealth Scientific And Industrial Research Organisation
|Asxl1 as a new diagnostic marker of myeloid neoplasms|
The present invention relates to a method for diagnosing a myeloid cancer in a subject, which comprises the step of analyzing a biological sample from said subject by determining the presence or the absence of a mutation in the asxl1 (additional sex combs like 1) gene coding for the polypeptide having the sequence seq id no 2. A kit for diagnosing myeloid cancer in a subject comprising at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method..
Inserm (institut National De La Santé Et De La Recherche Médicale)
|Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms|
Disclosed herein are methods for detecting, diagnosing and/or prognosing a malignant adrenocortical tumor. Also disclosed are methods of treating a malignant adrenocortical tumor, such as acc.
The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services
|Compositions and methods for treating b-lymphoid malignancies|
Compositions and methods for inhibiting, treating, and/or preventing a b-cell neoplasm are provided.. .
The Trustees Of The University Of Pennsylvania
|4-dedimethylamino tetracycline compounds|
The present invention pertains, at least in part, to novel substituted 4-dedimethylamino tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression..
Paratek Pharmaceuticals, Inc.
|Methods and materials for detecting gene amplification|
This document relates to methods and materials involved in detecting gene amplification in a mammal. For example, methods and materials for detecting amplification at cpm and mdm2 loci to determine the presence or absence of a malignant lipomatous neoplasm in a mammal are provided..
Mayo Foundation For Medical Education And Research
|Urea derivatives and uses thereof|
The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.
|Compositions and methods of use of phorbol esters in the treatment of neoplasms|
Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms, treatments, or sequelae of disease.
Biosuccess Biotech Co. Ltd.
|Gene biomarkers for prediction of susceptibility of ovarian neoplasms and/or prognosis or malignancy of ovarian cancers|
The present invention uses methylomic analysis and discovers dna methylation biomarkers for prediction of ovarian cancer prognosis and detection of malignant ovarian cancer. In addition to being independent prognostic factors for patients with current treatment protocols, these dna methylations are important biomarkers for individualized medicine for future chemotherapy (especially the demethylation agents or other epigenetic drugs)..
National Defense Medical Center
|Therapeutic applications of calcium electroporation to effectively induce tumor necrosis|
The present inventors have shown that electroporation with calcium ions are efficient on cutaneous and subcutaneous nodules. In particular the present inventors here disclose that a solution comprising calcium ions (ca2+) with a concentration of at least 0.1 m is extremely useful in a method of treating a neoplasm, such as cancer with means for causing transient permeabilisation of the cell membranes of at least part of the neoplasm before, during and/or after administration of said solution, wherein said solution is administered with a ratio of 0.2 to 0.8 of the volume of said part of the neoplasm..
Agent for treatment and prevention of cancer
The invention provides methods of treating or preventing in a subject a cancer, tumor, or neoplasm, including malignancies or metastases thereof, using a direct factor xa inhibitor. The methods particularly involve the treatment of human patients afflicted with a malignant cancer, tumor, or neoplasm with an effective amount of the factor xa inhibitor.
Daiichi Sankyo Company, Limited
Monitoring health and disease status using clonotype profiles
There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions.
Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
The present invention provides halofuginol, and derivatives and salts thereof, including diasteromerically enriched compositions thereof. The invention also provides pharmaceutical and cosmetic compositions thereof as well as methods for using halofuginol and derivatives thereof in treating chronic inflammatory diseases, autoimmune diseases, dry eye syndrome, fibrosis, scar formation, angiogenesis, viral infections, malaria, ischemic damage, transplant rejection, neurodegenerative diseases, t-cell neoplasms, and cosmetic conditions..
The General Hospital Corporation D/b/a Massachusetts General Hospital
Substituted tetracycline compounds
The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression..
Paratek Pharmaceuticals, Inc.
Methods for medical imaging
The invention relates to methods of identifying, detecting, and locating a tissue(s), nodule(s) or mass(es) and its draining lymph nodes that is/are suspected to be abnormal, typically a neoplasm (i.e., cancer, malignancy, premalignancy) in an individual undergoing an invasive procedure (i.e., surgery or endoscopy) or a non-invasive procedure (ie. Radiology).
The present invention relates generally to therapeutic compositions comprising chitosan-derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.. .
Method for the diagnosis of myeloid neoplasias and solid tumors and diagnostic kits
B) detecting the presence or absence of a mutation in the nucleic acid sample comprising the nf-e2 gene or a fragment thereof, characterized in that the presence of the mutation is an indication of a myeloid neoplasm or solid tumor, whereby the mutation is determined by comparing the nucleic acid sequence obtained from the sample with seq id no:1 or the complement thereof.. .
Compounds and methods for inhibition of ap endonuclease-1/redox factor-1 (hape1) activity
A method for treating a neoplasm in a subject, comprising co-administering to the subject a therapeutically effective amount of an anticancer agent and a substituted 6,7-methylenedioxy-4-amino-quinoline, or a pharmaceutically acceptable salt or ester thereof.. .
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
Gene expression signatures of neoplasm responsiveness to therapy
Gene signatures for determining whether a neoplasm (such as a multiple myeloma neoplasm) is sensitive to mtori/hdaci combination therapy and/or for determining the prognosis of a neoplasm in a subject are described. Some embodiments include determining whether a neoplasm is sensitive to mtori/hdaci combination therapy by predicting whether mtori/hdaci combination therapy will successfully treat the neoplasm, for example increasing survival of the subject with the neoplasm.
Intravascular cerebral catheter device and use
Cerebral catheter devices and methods for use are provided. The catheter devices provided may include an anti-thrombotic agent coating on the exterior surface.
Combination therapy using ribavirin as eif4e inhibitor
The present invention relates to pharmaceutical compositions and combination therapies for treating patents having a neoplasm or proliferative disorder, the combination comprises an inhibitor of the eif4e gene product and a chemotherapeutic agent, wherein said combination therapy overcomes resistance developed in patients during anti-neoplastic treatment. The present invention also provides for the use of a combination therapy for treating patients having a neoplasm, a proliferative disorder, pre-neoplasm or a precancerous lesion, comprising an inhibitor of the eif4e gene product, a chemotherapeutic agent, and a therapeutically effective amount of a hedgehog pathway inhibitor, and the method of using said combination therapy..
Kinase inhibitors and uses thereof
The present invention relates to kinase inhibiting compositions and uses thereof. The invention further provides isolated kinase inhibiting peptides and uses thereof for inhibiting hyperplasia, for inhibiting the growth of neoplasms, and for inducing programmed cell death in a cell population..
Neuron generation, regeneration and protection
The invention demonstrates that, contrary to apoptotic rabies virus g proteins, certain non-apoptotic rabies virus g proteins, such as the g protein of the cvs-niv strain, have a neurite outgrowth promoting effect. The invention further demonstrates that this neurite outgrowth promoting effect is due to the cytoplasmic tail of said non-apoptotic rabies virus g proteins, more particularly to their pdz-bs, which shows a single-point mutation compared to the one of apoptotic rabies virus g proteins.
Bioresorbable scaffold for neurologic drug delivery
Bioresorbable scaffolds and methods of treatment with such scaffolds for neurologic disorders including parkinson's disease, huntington's disease, alzheimer's disease, and brain neoplasms are disclosed. The bioresorbable scaffold includes a bioresorbable body and an active agent or drug associated with the body for treating or ameliorating the neurological disorder.
Differential identification of pancreatic cysts
More than 2% of adults harbor a pancreatic cyst, a subset of which progress to invasive lesions with lethal consequences. To assess the genomic landscapes of neoplastic cysts of the pancreas, we determined the exomic sequences of dna from the neoplastic epithelium of eight surgically resected cysts of each of the major neoplastic cyst types: serous cystadenomas (scas), intraductal papillary mucinous neoplasms (ipmns), mucinous cystic neoplasms (mcns) and solid pseudo-papillary neoplasms (spns).
Human homeobox gene ventx and macrophage terminal differentiation and activation, compositions and methods thereof
The invention relates to a unique formulated pharmaceutical composition and a novel treatment method of intratumoral injection. The pharmaceutical composition of the invention is the saturated ionic solution of sodium ions and calcium ions (the “medicinal ion bomb”).
Dna methylation in colorectal and breast cancer diagnostic methods
The present invention relates generally to nucleic acid molecules in respect of which changes to dna methylation levels are indicative of the onset or predisposition to the onset of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to dna methylation levels are indicative of the onset and/or progression of a large intestine or breast neoplasm, such as an adenoma or adenocarcinoma.
9-aminomethyl substituted minocycline compounds
The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression..
Products useful for the treatment of malignant neoplasms of the human nervous system
The application provides products, which may trigger pro-apoptotic or pro-death effects on neoplastic cells and/or tissues of the human nervous system, more particularly on neoplastic cells and/or tissues of the human cns. The products of the application can be used as anti-proliferative or tumoricid agents in the treatment and/or palliation and/or prevention of neoplasms of the human nervous system, more particularly of glioblastoma or brain stem glioma.
Apoptosis inducing compounds
The present invention relates to compounds of formula (i), wherein r1, r2, r3, r4 and r5 are independently selected from the group comprising, inter aliae, h, optionally substituted, branched or linear c1-c12 alkyl, halogen atom and c1-c12 haloalkyl, and wherein a represents a single bond or an optionally substituted c1-c6 alkylene radical, notably useful for the treatment of human neoplasms.. .
Method of diagnosing neoplasms - ii
The present invention relates generally to nucleic acid molecules in respect of which changes to the dna or to the rna or protein expression profiles are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules in respect of which changes to the dna or to the rna or protein expression profiles are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma.
Provided herein is technology relating to detecting neoplasia and particularly, but not exclusively, to methods, compositions, and related uses for detecting premalignant and malignant neoplasms such as pancreatic and colorectal cancer.. .
Monitoring treatment-resistant clones in lymphoid and myeloid neoplasms by relative levels of evolved clonotypes
The invention is directed to a method of monitoring or detecting treatment-resistant clones in a patient being treated for a lymphoid or myeloid neoplasm from which patient-specific correlating clonotypes have been identified. In some embodiments, such method includes the steps of obtaining a sample from the patient comprising t-cells and/or b-cells; amplifying molecules of nucleic acid from the t-cells and/or b-cells of the sample, the molecules of nucleic acid comprising recombined dna sequences from t-cell receptor genes or immunoglobulin genes; sequencing the amplified molecules of nucleic acid to form a clonotype profile; determining from the clonotype profile a level of each correlating clonotype and clonotypes clonally evolved therefrom; and correlating a presence of a treatment-resistant clone of the neoplasm with a change in relative levels of the correlating clonotypes and clonotypes clonally evolved therefrom.
Vimentin as a biomarker for the progression of myeloproliferative neoplasms
The disclosure relates to novel compounds that are capable of modulating jak2 kinase activities, compounds that have therapeutic use in treating or preventing a subject suffering from or susceptible to a jak2 mediated disease or disorder, and methods of use and compositions thereof.. .
Hematopoietic neoplasm chemotherapy
A method and medicament for treating mixed lineage leukemia; translocated mixed lineage leukemia; translocated mixed lineage leukemia based acute myelogenous leukemia; translocated mixed lineage leukemia based acute lymphoid leukemia; a non-mll based chronic myeloproliferative disorder, or non-mll based acute lymphoid leukemia is provided.. .
Methods and tools for the diagnosis and prognosis of urogenital cancers
The present invention provides a microarray useful as a tool in the diagnosis and/or prognosis of certain types of cancers, particularly urogenital cancers. The microarray can include a plurality of genomic regions represented thereon, the genomic regions corresponding to regions wherein alterations, such as copy number aberrations, at such locations correlate to specific, identifiable cancers, particularly prostate, renal, or bladder tumors.
Monitoring health and disease status using clonotype profiles
There is a need or improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions.
Method for assessing progression of clinical state of malignant neoplasm by quantitative detection of dna in blood
The object of the invention is to provide a method for quantitatively assessing the degree of progression of a malignant neoplasm in a patient who has been medicated. Provided is a method for assessing the progression of the clinical state of a malignant neoplasm in a subject who has been administered with a medicine for treating the malignant neoplasm, the method being characterized by comprising: (1) a step of determining the ratio of dna molecules having an activation mutation that serves as an activation marker for the medicine to dna molecules having a normal marker gene in dna in the blood from the subject; (2) a step of determining the ratio of dna molecules having a resistance mutation that serves as a resistance marker for the medicine to dna molecules having a normal marker gene in the dna in the blood from the subject; and (3) a step of comparing a value obtained in the step (2) with a value obtained in the step (1) to thereby assess whether or not the malignant neoplasm in the subject has acquired resistance to the treatment with the medicine..
Method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression o caveolin-1, caveolin-2, vimentin, calponin2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, ef-i-delta, or m2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm.. .
This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided..
Methods and compositions for single chain variable region enox2 antibodies for cancer detection and diagnosis
All neoplastic cells express one or more members of a unique family of cell surface ubiquinone (nadh) oxidase proteins with protein disulfide-thiol interchange activity (ecto-nox proteins) that are characteristically inhibited by quinone site inhibitors with anti-cancer activity and a common amino acid sequence disclosed herein that allows for cancer-specific antibody recognition as well as for detection of certain critical reference proteins that provide loading controls. Cancers of different cellular or tissue origins express different enox2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation.
Compositions and methods for inhibiting ccl3
The present invention relates to the discovery that ccl3, through at least one of its receptors ccr1 and ccr5, plays a role in the pathologies associated with myeloid neoplasms. In various embodiments, the pathologies associated with myeloid neoplasms treatable by the compositions and methods of the invention described herein include, but are not limited to, at least one of osteoclast/osteoblast imbalance, inhibition of osteoblast function, bone loss, disregulation of the hematopoietic stem cell microenvironment, abnormal hematopoietic recovery, pancytopenia, anemia, thrombocytopenia, neutropenia, bicytopenia, and erythrocytopenia.
Mutations in pancreatic neoplasms
To help reveal the pathogenesis of these lesions, we purified the dna from intraductal papillary mucinous neoplasm (ipmn) cyst fluids from 19 patients and searched for mutations in 169 genes commonly altered in human cancers. We identified recurrent mutations at codon 201 of gnas.
Modulators of adp-dependent glucokinase (adpgk) and glycerol-3-phosphate dehydrogenase (gpd2) for therapy
Described are compounds capable of modulating (a) the biological activity of adp-dependent glucokinase (adpgk) and/or glycerol-3-phosphate dehydrogenase (gpd2) or (b) the expression of the gene encoding adpgk or gpd2 for use in treating a disease (a) associated with aberrant cell proliferation, e.g., a neoplasm, or (b) of the immune system, e.g., an autoimmune disease.. .
Cephalotaxus esters, methods of synthesis, and uses thereof
The present invention provides novel cephalotaxus esters, syntheses thereof, and intermediates thereto. The invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of using said compounds or compositions in the treatment of proliferative diseases (e.g., benign neoplasm, cancer, inflammatory disease, autoimmune disease, diabetic retinopathy) and infectious disease.
Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
A combination of a 4-anilino-3-cyanoquinoline compound (e.g. Hki-272, ski-606, ekb-569) and a capecitabine compound in the treatment of a neoplasm is provided.
Popular terms: [SEARCH]
Neoplasm topics: Autoimmune Disease, Autoimmune, Immune Disease, Neurotoxin, Graft Versus Host Disease, Botulinum Toxin, Modulation, Human Papillomavirus, Antibodies, Ascorbic Acid, Neoplastic, Proliferative, Epithelial, Neuroblastoma, Osteosarcoma
Follow us on Twitter
This listing is a sample listing of patent applications related to Neoplasm for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Neoplasm with additional patents listed. Browse our RSS directory or Search for other possible listings.